UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
VERV holding history
Verve Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VERV overviewAll 13F holders of VERVFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −1,870,522−100.0% | Sold out | Holders |
| Q2 2025 | 1,870,522 | $21.0M | <0.1% | +1,738,749+1,319.5% | Added | Holders |
| Q1 2025 | 131,773 | $602.2K | <0.1% | −8,016−5.7% | Reduced | Holders |
| Q4 2024 | 139,789 | $788.4K | <0.1% | −24,338−14.8% | Reduced | Holders |
| Q3 2024 | 164,127 | $794.4K | <0.1% | +57,425+53.8% | Added | Holders |
| Q2 2024 | 106,702 | $520.7K | <0.1% | −185,282−63.5% | Reduced | Holders |
| Q1 2024 | 291,984 | $3.88M | <0.1% | +88,633+43.6% | Added | Holders |
| Q4 2023 | 203,351 | $2.83M | <0.1% | +120,088+144.2% | Added | Holders |
| Q3 2023 | 83,263 | $1.10M | <0.1% | −4,811−5.5% | Reduced | Holders |
| Q2 2023 | 88,074 | $1.65M | <0.1% | −2,761−3.0% | Reduced | Holders |
| Q1 2023 | 90,835 | $1.31M | <0.1% | −152,939−62.7% | Reduced | Holders |
| Q4 2022 | 243,774 | $4.72M | <0.1% | +210,071+623.3% | Added | Holders |
| Q3 2022 | 33,703 | $1.16M | <0.1% | +33,553+22,368.7% | Added | Holders |
| Q2 2022 | 150 | $2.00K | <0.1% | −106,101−99.9% | Reduced | Holders |
| Q1 2022 | 106,251 | $2.42M | <0.1% | +81,921+336.7% | Added | Holders |
| Q4 2021 | 24,330 | $897.0K | <0.1% | +21,030+637.3% | Added | Holders |
| Q3 2021 | 3,300 | $155.0K | <0.1% | +1,769+115.5% | Added | Holders |
| Q2 2021 | 1,531 | $92.0K | <0.1% | +1,531 | New | Holders |